Globe Life Sees FY26 EPS of $14.95-$15.65
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4d ago
0mins
Should l Buy GL?
Globe Life sees FY26 EPS $14.95-$15.65, consensus $15.03
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GL
Wall Street analysts forecast GL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GL is 170.88 USD with a low forecast of 155.00 USD and a high forecast of 199.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 146.950
Low
155.00
Averages
170.88
High
199.00
Current: 146.950
Low
155.00
Averages
170.88
High
199.00
About GL
Globe Life Inc. is an insurance holding company. Its primary subsidiaries are Globe Life And Accident Insurance Company, American Income Life Insurance Company, Liberty National Life Insurance Company, Family Heritage Life Insurance Company of America, and United American Insurance Company. The Company’s segments include life insurance, supplemental health insurance, and investments. Life insurance products include traditional whole life and term life insurance. The Company offers Medicare Supplement and limited-benefit supplemental health insurance products that include accident, cancer, critical illness, heart, intensive care, and other health products. These products are designed to supplement health coverage that applicants already own. Medicare Supplements are offered to enrollees in the traditional fee-for-service Medicare program. Medicare Supplement plans are standardized by federal regulation and are designed to pay deductibles and co-payments not paid by Medicare.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Insider at Globe Life (GL.US) Files Form 144 to Sell $6.61 Million in Common Stock
- Stock Sale Announcement: Insider James Matt Darden plans to sell 45,000 shares of its common stock on February 6.
- Market Value: The total market value of the shares being sold is approximately $6.61 million.
See More
Insider at Globe Life (GL.US) Files Form 144 to Sell 4.41 Million Shares of Common Stock
- Stock Sale Announcement: Michael C. Majors intends to sell 30,000 shares of its common stock on February 6.
- Market Value: The total market value of the shares being sold is approximately $4.41 million.
See More
Globe Life Inc. Reports Strong Q4 2025 Earnings and Growth Outlook
- Net Income Growth: Globe Life reported a net income of $266 million for Q4 2025, translating to $3.29 per share, which marks an increase from $255 million or $3.01 per share a year earlier, indicating sustained profitability improvements.
- Premium Revenue Increase: Total premium revenue for the fourth quarter grew by 5% year-over-year, with life premium revenue at $850 million and health insurance premium revenue rising 9% to $392 million, reflecting the company's competitive strength and heightened customer demand.
- Optimistic Future Outlook: Management projects total premium revenue growth of 7% to 8% for 2026, with life premiums expected to rise by 4% to 4.5% and health premiums projected to increase by 14% to 16%, demonstrating confidence in future market opportunities.
- Share Repurchase Program: The company repurchased approximately 1.3 million shares of common stock in Q4 at a total cost of about $170 million, averaging $134.44 per share, indicating a commitment to shareholder returns and confidence in its stock value.
See More
Globe Life Reports Increased Q4 Profit and Revenue Growth
- Profit Growth: Globe Life Inc. reported a fourth-quarter profit of $0.266 million, translating to $3.29 per share, which is an increase from last year's $0.255 million and $3.01 per share, indicating improved profitability that boosts investor confidence.
- Revenue Increase: The company's revenue rose by 3.6% in the fourth quarter, from $1.466 million to $1.519 million, reflecting stable business growth and improved market demand, potentially laying the groundwork for future expansion.
- Performance Comparison: Compared to the same period last year, Globe Life's earnings per share and total revenue both increased, demonstrating the company's strong performance in a competitive insurance market, thereby enhancing its market position.
- Investor Outlook: With the growth in profit and revenue, Globe Life may attract more investor attention, further driving up stock prices and enhancing the company's competitiveness within the industry.
See More
Globe Life Reports Q4 Net Income Growth
- Net Income Growth: Globe Life reported a Q4 2025 net income of $3.29 per diluted share, a 9.3% increase from $3.01 in the same quarter last year, indicating sustained profitability that is likely to positively impact stock prices.
- Operating Income Increase: The company achieved a net operating income of $3.39 per diluted share in Q4 2025, up 7.9% from $3.14 in the previous year, reflecting robust performance in its insurance business and further solidifying its market position.
- Underwriting Income Rise: Insurance underwriting income reached $359.738 million in Q4 2025, a 6.4% increase from $337.984 million in the prior year, demonstrating the company's competitive strength in the life and health insurance markets, which is expected to drive future revenue growth.
- Share Repurchase Program: The company repurchased 1.3 million shares of its common stock at a total cost of $170 million during Q4 2025, with an average share price of $134.44, reflecting confidence in its stock value and potentially enhancing earnings per share.
See More
Globe Life to Announce Q4 2025 Financial Results
- Earnings Announcement Schedule: Globe Life Inc. will release its Q4 2025 financial results after market close on February 4, 2026, providing crucial financial data and statistics to ensure timely information access for investors.
- Conference Call Timing: The company will host a conference call on February 5, 2026, at 11:00 AM Eastern (10:00 AM Central), allowing investors to dial in at 1-646-357-8766 (passcode: Globe Life Inc.) for further insights into its financial performance.
- Online Access Convenience: Investors can access the earnings report through the “Financial Reports and Other Financial Information” section on the company’s website, and listen to the live and replay of the call under the “Calls and Meetings” section, enhancing information transparency and accessibility.
- Market Positioning: Globe Life Inc. specializes in life and supplemental health insurance for the middle-income market, distributed through various channels including direct-to-consumer and independent agencies, showcasing its diversified strategy within the insurance sector.
See More
Insider at Globe Life (GL.US) Files Form 144 to Sell $6.61 Million in Common Stock
- Stock Sale Announcement: Insider James Matt Darden plans to sell 45,000 shares of its common stock on February 6.
- Market Value: The total market value of the shares being sold is approximately $6.61 million.
See More
Insider at Globe Life (GL.US) Files Form 144 to Sell 4.41 Million Shares of Common Stock
- Stock Sale Announcement: Michael C. Majors intends to sell 30,000 shares of its common stock on February 6.
- Market Value: The total market value of the shares being sold is approximately $4.41 million.
See More
Globe Life Inc. Reports Strong Q4 2025 Earnings and Growth Outlook
- Net Income Growth: Globe Life reported a net income of $266 million for Q4 2025, translating to $3.29 per share, which marks an increase from $255 million or $3.01 per share a year earlier, indicating sustained profitability improvements.
- Premium Revenue Increase: Total premium revenue for the fourth quarter grew by 5% year-over-year, with life premium revenue at $850 million and health insurance premium revenue rising 9% to $392 million, reflecting the company's competitive strength and heightened customer demand.
- Optimistic Future Outlook: Management projects total premium revenue growth of 7% to 8% for 2026, with life premiums expected to rise by 4% to 4.5% and health premiums projected to increase by 14% to 16%, demonstrating confidence in future market opportunities.
- Share Repurchase Program: The company repurchased approximately 1.3 million shares of common stock in Q4 at a total cost of about $170 million, averaging $134.44 per share, indicating a commitment to shareholder returns and confidence in its stock value.
See More
Globe Life Reports Increased Q4 Profit and Revenue Growth
- Profit Growth: Globe Life Inc. reported a fourth-quarter profit of $0.266 million, translating to $3.29 per share, which is an increase from last year's $0.255 million and $3.01 per share, indicating improved profitability that boosts investor confidence.
- Revenue Increase: The company's revenue rose by 3.6% in the fourth quarter, from $1.466 million to $1.519 million, reflecting stable business growth and improved market demand, potentially laying the groundwork for future expansion.
- Performance Comparison: Compared to the same period last year, Globe Life's earnings per share and total revenue both increased, demonstrating the company's strong performance in a competitive insurance market, thereby enhancing its market position.
- Investor Outlook: With the growth in profit and revenue, Globe Life may attract more investor attention, further driving up stock prices and enhancing the company's competitiveness within the industry.
See More
Globe Life Reports Q4 Net Income Growth
- Net Income Growth: Globe Life reported a Q4 2025 net income of $3.29 per diluted share, a 9.3% increase from $3.01 in the same quarter last year, indicating sustained profitability that is likely to positively impact stock prices.
- Operating Income Increase: The company achieved a net operating income of $3.39 per diluted share in Q4 2025, up 7.9% from $3.14 in the previous year, reflecting robust performance in its insurance business and further solidifying its market position.
- Underwriting Income Rise: Insurance underwriting income reached $359.738 million in Q4 2025, a 6.4% increase from $337.984 million in the prior year, demonstrating the company's competitive strength in the life and health insurance markets, which is expected to drive future revenue growth.
- Share Repurchase Program: The company repurchased 1.3 million shares of its common stock at a total cost of $170 million during Q4 2025, with an average share price of $134.44, reflecting confidence in its stock value and potentially enhancing earnings per share.
See More
Globe Life to Announce Q4 2025 Financial Results
- Earnings Announcement Schedule: Globe Life Inc. will release its Q4 2025 financial results after market close on February 4, 2026, providing crucial financial data and statistics to ensure timely information access for investors.
- Conference Call Timing: The company will host a conference call on February 5, 2026, at 11:00 AM Eastern (10:00 AM Central), allowing investors to dial in at 1-646-357-8766 (passcode: Globe Life Inc.) for further insights into its financial performance.
- Online Access Convenience: Investors can access the earnings report through the “Financial Reports and Other Financial Information” section on the company’s website, and listen to the live and replay of the call under the “Calls and Meetings” section, enhancing information transparency and accessibility.
- Market Positioning: Globe Life Inc. specializes in life and supplemental health insurance for the middle-income market, distributed through various channels including direct-to-consumer and independent agencies, showcasing its diversified strategy within the insurance sector.
See More
